Clinical Recommendation for the Use of Injectable Lenacapavir ... This report describes a clinical recommendation to use injectable lenacapavir as an HIV preexposure prophylaxis.

New CDC guidelines recommend twice-a-year injectable lenacapavir as a new option for #HIV prevention. FDA approved this medication in June 2025, expanding HIV PrEP options with the potential to advance efforts to end the HIV epidemic. #FundHIV. Read the full clinical recommendation: bit.ly/47WMx5P

Dealing with a Republican Congress to save HIV programs | Positively Aware

🚨 HIV advocates are rallying to #SaveHIVFunding as cuts loom.

“We were all very pleasantly surprised,” said NASTAD’s Emily McCloskey Schreiber on Rep. Lawler’s GOP support for HIV prevention.

More via @posaware.bsky.social: www.positivelyaware.com/articles/dea...

#FundHIV #AIDSWatch #NASTAD

#ICYMI 📣 On #NWGHAAD, we highlighted PEPFAR’s vital impact on women & girls. Since 2003, #PEPFAR has saved millions of lives by expanding access to HIV testing, PrEP, & ART. Continued funding is critical to sustain these efforts.

Learn more: nastad.org/blog/importa...
#FundHIV #GlobalHealth

📢 NEW STATEMENT📢 Today, NASTAD and our partners released a statement urging continued investment in #HIV prevention funding. Without sustained support, we risk reversing decades of progress in preventing HIV, hepatitis, and STIs.

Read the full statement: nastad.org/blog/partner... #FundHIV